The course of peripheral neuropathy and its association with health-related quality of life among colorectal cancer patients

Abstract

Purpose To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. Methods All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. Results Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. Conclusions Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient’s lives. Implications for cancer survivors Patients need to be informed of both CIPN and the impact on HRQoL.

Exploring the relationship among dispositional optimism, health-related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy

“…Details of the data collection procedure have been described previously [20]. Data collection was performed via the PROFILES registry (www.…”

“…We use data from the longitudinal PROCORE study that assessed CRC patients before treatment and at one-and 2-year follow-up. A recent publication on the course of (CI) PN using this dataset revealed that 57% and 47% of the sample that was treated with chemotherapy experienced clinically relevant sensory peripheral neuropathy (SPN) one and 2 years after diagnosis, respectively [20]. SPN was prospectively associated with significantly worse global HRQoL and worse physical, role, emotional, cognitive, and social functioning over time.…”

Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy

“…Ezzi et al [ 11 ] also showed that, of patients who underwent chemotherapy with cisplatin for at least 2 months at Kenyatta National Hospital oncology units, 56 patients (83.6%) had peripheral neuropathy; 45 patients (81%) had mild-grade (grades 1 and 2) peripheral neuropathy and only two patients (3.1%) had grade 4 neuropathy. The neuropathy symptoms may cause dose reduction [ 12 ], refusal to continue treatment [ 13 ], psychological distress [ 14 ], neurological impairment [ 15 ], and reduced quality of life (QoL) [ 16 , 17 ].…”

Impact of Chemotherapy-induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-based Chemotherapy

“…A holistic approach -including patient health education, dietary adjustment, nutritional supplements, aerobic exercise, and balance training -is needed to relieve the distressful peripheral neurological symptoms and emotional distress of CIPN during and after treatment for advanced LC. cause dose reduction [8], refusal to continue treatment [9], psychological distress [10], neurological impairment [11], and reduced quality of life (QoL) [12,13].Although previous studies have explored these issues, most research has focused on patients with colorectal cancer [14-16], breast cancer [17], or those in Western countries [18][19][20]; or on other chemotherapy regimens such as taxane [18,19], paclitaxel [19,20], or carboplatin [19,20]. Clinical observation indicates that LC patients treated with platinum-based regimens report CIPN-related symptoms that affect daily function and QoL, and insu cient attention has been devoted to this important topic.…”

“…A holistic approach -including patient health education, dietary adjustment, nutritional supplements, aerobic exercise, and balance training -is needed to relieve the distressful peripheral neurological symptoms and emotional distress of CIPN during and after treatment for advanced LC. cause dose reduction [8], refusal to continue treatment [9], psychological distress [10], neurological impairment [11], and reduced quality of life (QoL) [12,13].…”